For Research Use Only

Upadacitinib

www.ptgcn.com

Catalog Number: CM04911

产品信息

Catalog Number:
CM04911

CAS号:
1310726-60-3

分子式:
$C_{17}H_{19}F_3N_6O$

主要靶点:
JAK

主要通路:
JAK/STAT信号通路|表观遗传|干细胞|血管生成

分子量:
380.37

溶解度:
DMSO:22 mg/mL



靶点活性

JAK1:43 nM|JAK2:200 nM

体外活性

Upadacitinib is 74-fold more selective for JAK-1 than for JAK-2, which is involved in erythropoiesis. And Upadacitinib is 58-fold more selective for JAK-1 than for JAK-3, which is involved in immunosurveillance. The enhanced selectivity of Upadacitinib for JAK-1 over JAK-2 and JAK-3 may offer an improved benefit-risk profile in patients with RA range.

体内活性

Upadacitinib, a second JAK inhibitor, has been developed by AbbVie.Upadacitinib finished multiple-dose Phase I studies in 2013. Upadacitinib show to be safe and well-tolerated up to multiple doses of 24 mg twice daily using the immediate release formulation in phase I trials. Upadacitinib exposure is dose proportional to the evaluated multiple dose.

描述

Upadacitinib (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM.

储存

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

For technical support and original validation data for this product please contact
T: 027-87531629 E: Proteintech-CN@ptglab.com W: ptgcn.com